Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective Kenneth BoydPeter Hall Editorial 20 February 2016 Pages: 529 - 531
Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension Shuyan GuHuimei HuHengjin Dong Systematic Review 29 December 2015 Pages: 533 - 550
Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals Jagpreet ChhatwalTianhua HeMaria A. Lopez-Olivo Systematic Review 09 January 2016 Pages: 551 - 567
A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus Martin HenrikssonRamandeep JindalMichael Willis Systematic Review 20 January 2016 Pages: 569 - 585
Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence Sebastian HindeRos WadeEldon Spackman Review Article 28 January 2016 Pages: 587 - 596
Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search Requirement Suzy Paisley Practical Application 09 February 2016 Pages: 597 - 608
Biosimilars: How Can Payers Get Long-Term Savings? Jorge Mestre-FerrandizAdrian TowseMikel Berdud Current Opinion Open access 20 January 2016 Pages: 609 - 616
Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health Salah GhabriFrançoise F. HamersJean Michel Josselin Original Research Article 30 January 2016 Pages: 617 - 624